Prevention of peritoneal adhesions: A promising role for gene therapy

Hussein M Atta

Hussein M Atta, Department of Surgery, Faculty of Medicine, Minia University, El-Minia 61519, Egypt
Author contributions: Atta HM solely contributed to this paper.
Supported by: The United States-Egypt Science and Technology Joint Fund in cooperation with United States Department of Agriculture and the Egyptian Science and Technology Development Fund under Project 739
Correspondence to: Hussein M Atta, MD, PhD, Professor, Department of Surgery, Faculty of Medicine, Minia University, Misr-Aswan Road, El-Minia 61519, Egypt. attahm@ems.org.eg
Telephone: +20-1-001407222 Fax: +20-2-22917077
Received: May 15, 2011 Revised: July 14, 2011 Accepted: July 21, 2011 Published online: December 14, 2011

Abstract
Adhesions are the most frequent complication of abdominopelvic surgery, yet the extent of the problem, and its serious consequences, has not been adequately recognized. Adhesions evolved as a life-saving mechanism to limit the spread of intraperitoneal inflammatory conditions. Three different pathophysiological mechanisms can independently trigger adhesion formation. Mesothelial cell injury and loss during operations, tissue hypoxia and inflammation each promotes adhesion formation separately, and potentiate the effect of each other. Studies have repeatedly demonstrated that interruption of a single pathway does not completely prevent adhesion formation. This review summarizes the pathogenesis of adhesion formation and the results of single gene therapy interventions. It explores the promising role of combinatorial gene therapy and vector modifications for the prevention of adhesion formation in order to stimulate new ideas and encourage rapid advancements in this field.

© 2011 Baishideng. All rights reserved.

Key words: Peritoneal adhesions; Tissue plasminogen activator; Gene therapy; Plasminogen activator inhibitor; Tissue inhibitor of metalloproteinase; Transforming growth factor β

Peer reviewer: Michael E Zenilman, MD, Clarence and Mary Dennis Professor and Chairman, Department of Surgery, SUNY Downstate Medical Center, PO Box 40, 450 Clarkson Avenue, Brooklyn, NY 11202, United States

Atta HM. Prevention of peritoneal adhesions: A promising role for gene therapy. World J Gastroenterol 2011; 17(46): 5049-5058 Available from: URL: http://www.wjgnet.com/1007-9327/full/v17/i46/5049.htm DOI: http://dx.doi.org/10.3748/wjg.v17.i46.5049

INTRODUCTION
Peritoneal adhesions are abnormal deposits of fibrous tissue that occur in the peritoneal cavity as a result of surgery or peritonitis, or their combination. Adhesions occur in more than 90% of patients following abdominal or pelvic surgery[1,2], and are only moderately reduced after laparoscopic surgical procedures compared to open surgery[3,4]. Adhesion reformation occurs postoperatively in 85% of patients, regardless of whether the adhesiolyis is performed via laparotomy or laparoscopy[5].

Intraperitoneal adhesions are a major source of morbidity, being the commonest cause of intestinal obstruction[6,7], secondary female infertility, and ectopic gestation[8,9]. They may also cause chronic abdominal and pelvic pain[10,11]. Small bowel obstruction is the most serious consequence of intra-abdominal adhesions. retrospective studies have shown that 32%–75% of patients who require abdominal re-operation have adhesion-related intestinal obstruction[12,13].

Adhesions result in a large surgical workload and cost to health care systems. An epidemiological study in the United States showed that 282,000 hospital admissions in 1988 were due to adhesion-related disorders, and the cost
of in-patient adhesiolysis was $1.18 billion. In 1994, 1% of all United States admissions involved adhesiolysis treatment, resulting in $1.33 billion in health care expenditure.

Adhesions and their associated complications are of rising medico-legal interest. Physicians worldwide need to be aware of the increasing burden of medico-legal claims arising from the complications of intra-abdominal adhesions. Successful medico-legal claims include cases of bowel perforation after laparoscopic division of adhesions, delays in the diagnosis of adhesion obstruction of the small bowel, infertility as a result of adhesions, and pain.

Currently, there is no effective method for preventing adhesion formation or reformation. A better understanding of the pathogenesis of adhesion formation at the cellular and molecular level would undoubtedly help to develop more effective treatment strategies.

### PATHOGENESIS

**Vicious triad of trauma, hypoxia, and inflammation**

The peritoneum is lined by mesothelial cells loosely attached to the basement membrane, which can readily be detached by the slightest trauma. After injury to the peritoneum, a local inflammatory reaction causes increased vascular permeability in blood vessels supplying the damaged area, followed by an exudation of serosanguinous fluid rich in fibrin and inflammatory cells, ultimately leading to the formation of a fibrin matrix. Normally, the plasminogen activator activity (PAA), which resides in the mesothelial cells and submesothelial fibroblasts, degrades the fibrinous mass, resulting in healing of peritoneal surfaces (within three to five days) without adhesions. However, if the level of PAA is diminished, the fibrinous mass persists and the underlying fibroblasts migrate into the fibrinous mass. The fibroblasts then deposit extracellular matrix, including collagen and fibronectin, leading to adhesion formation. Over time, the adhesion may provide the framework for vascular ingrowth, during the process of angiogenesis.

The pathogenesis of adhesions involves three important trauma-induced processes (Figure 1): (1) trauma induces inhibition of the fibrinolytic and extracellular matrix (ECM) degradation systems; (2) trauma, as well as foreign bodies, incites an inflammatory response with the production of cytokines, mainly transforming growth factor-β (TGF-β), a key regulator of tissue fibrosis; and (3) trauma also induces tissue hypoxia as a result of interruption of the blood supply to mesothelial cells and submesothelial fibroblasts, leading to increased expression of hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF), responsible for collagen formation and angiogenesis.

### MOLECULAR CROSSTALK

**Sticky connected pathways**

Molecular pathways involved in fibrinolysis inhibition, inflammation, and tissue hypoxia crosstalk and potentiate the effect of each. The principal molecular aberrations included in this crosstalk are the reduction of tissue plasminogen activator (tPA) and upregulation of TGF-β1 and HIF-1α.

### INHIBITION OF FIBRINOLYSIS AND MATRIX DEGRADATION

The role of fibrinolysis in adhesion formation/reformation is to breakdown the fibrin clots that are formed during the healing process. The inactive proenzyme, plasminogen, is converted to plasmin by the action of tPA. Plasmin degrades fibrin and thus limits adhesion formation. Experimental and clinical studies have identified the presence of PAA in the mesothelium and that tPA is the major physiological mediator of PAA. Both mechanical and chemical injury reduce peritoneal PAA, with a progressive reduction in PAA in the first hours following a surgical operation, followed by complete loss of fibrinolytic activity up to 72 h after the operation. Laparoscopic surgery also decreases peritoneal tPA. This reduction in PAA is the result of reduced tPA production and increased release of plasminogen activator inhibitors 1 and 2 (PAI-1, PAI-2) by mesothelial, endothelial, and inflammatory cells. Extensive human and animal studies confirmed the central role of altered tPA/PAI-1 balance in adhesion formation and demonstrated that this imbalance is more exaggerated in severe adhesions. Plasmin also activates latent matrix metalloproteinases (MMPs) involved in extracellular matrix (ECM) degradation. The proteolytic activity of MMPs is regulated in part by their physiological inhibitors, tissue inhibitors of MMPs (TIMPs). It has been shown that MMPs and TIMPs are ex-
pressed in the human peritoneum, in adhesion fibroblasts, and in serosal layers of several intraperitoneal organs with and without adhesions\textsuperscript{3,41,42}. Chegini et al\textsuperscript{50} demonstrated that serosal tissue of intraperitoneal organs obtained during open surgery expresses more tissue inhibitor metalloproteinase-1 (TIMP-1) than matrix metalloproteinase-1 (MMP-1), and that adhesions express elevated levels of TIMP-1 and a lower ratio of MMP-1 to TIMP-1 compared with intact parietal peritoneum. The association between the imbalance of MMP/TIMP production and adhesion formation has been confirmed in another study in women undergoing laparoscopy\textsuperscript{59}.

INFLAMMATION AND THE ROLE OF TRANSFORMING GROWTH FACTOR-β-1

Several studies have demonstrated that during the acute phase of the inflammatory response, mesothelial cells and peritoneal macrophages produce a variety of cytokines, including TGF-β1, tumor necrosis factor α (TNF-α), interleukin-1 (IL-1), and IL-6. These pro-inflammatory cytokines, individually and synergistically, stimulate the production of PAI-1 and reduce the synthesis of tPA by human mesothelial cells (Figure 1)\textsuperscript{27,44,46}. TGF-β not only interacts with the fibrinolytic system and ECM, but also with many other cellular mediators involved in the process of adhesion formation. TGF-β1 overexpression by the peritoneum, as well as increased concentrations of TGF-β in the peritoneal fluid, has been associated with increased incidence of adhesion formation in both humans and animals\textsuperscript{3,27,47,48}.

Several studies demonstrated that increased TGF-β1 is associated with a reduction of tPA and an increase of PAI-1 release\textsuperscript{27,49,50}, an excess of TGF-β1 leads to an increase in the severity of adhesions formed\textsuperscript{52,53}, whereas an inhibitory antibody to TGF-β1 decreased adhesion formation\textsuperscript{53}. TGF-β1 contributes to the synthesis of the ECM by stimulating fibroblastic cell production of collagen and fibronectin\textsuperscript{53-55}. TGF-β also antagonizes ECM resorption by decreasing the activity of MMPs through decreasing MMP-1 and increasing TIMP-1 expression from mesothelial cells\textsuperscript{53,56,57}. This impairment of MMP activity prevents the ECM deposition that occurs early in wound healing from being adequately remodeled and degraded when necessary, as healing progresses.

THE ROLE OF HYPOXIA IN ADHESION FORMATION

Several lines of evidence have demonstrated that peritoneal tissue hypoxia plays a key role in adhesion formation\textsuperscript{52,61}. During laparotomy, tissue injury including trauma, desiccation, and vascular disruption (due to ligatures and other vascular hemostatic methods, including cauterization) reduces oxygen supply to the peritoneum. Laparoscopic surgery was shown to be less adhesiogenic, not only because it is less traumatic, but also due to elevated peritoneal tissue oxygen tension levels compared to those during laparotomy\textsuperscript{58}. However, adhesions during laparoscopic surgery increase with duration of pneumoperitoneum and with insufflation pressure. These effects were attributed to desiccation and compression of the capillary flow in the superficial peritoneal layers by the pneumoperitoneum. The addition of oxygen to the insufflation gas decreases adhesion formation\textsuperscript{59}. Moreover, supplemental perioperative oxygen was found to increase peritoneal tissue oxygen tension and to reduce the severity of adhesions\textsuperscript{60}.

Hypoxia negatively modulates all pathways involved in adhesion formation. Hypoxia decreases PAI and increases PAI-1 expression in human peritoneal fibroblasts \textit{in vitro}\textsuperscript{60} and in peritoneal tissues \textit{in vivo}\textsuperscript{61}, thereby decreasing plasmin, inhibiting lysis of fibrin, and increasing adhesion formation. The PAI-1 gene contains oxygen responsive promoter sequences, namely hypoxia response element (HRE-1 and HRE-2), to which HIF-1α binds and induces gene expression\textsuperscript{62}. Hypoxia was found to increase expression of TIMP-1, but not MMP-1, in both peritoneal and adhesion fibroblasts\textsuperscript{85}, thus decreasing matrix degradation. Hypoxic conditions in cultured human mesothelial cells and peritoneal fibroblasts also increased the expression of TGF-β1\textsuperscript{53,64,65}. Hypoxia resulted in increased expression of collagen 1 mRNA in both peritoneal and adhesion fibroblasts\textsuperscript{66}, probably through the production of superoxide\textsuperscript{67}. Moreover, hypoxia induces proliferation while inhibiting apoptosis in fibroblasts from adhesion, thus favoring adhesion formation\textsuperscript{68}. Finally, hypoxia increases VEGF production through activation of HIF-1α in normal and adhesion fibroblasts \textit{in vitro}\textsuperscript{69} and \textit{in vivo} in human adhesion mesothelial cells\textsuperscript{69} and in animal adhesion tissues\textsuperscript{70,71}. VEGF plays a central role in angiogenesis and its role in adhesion blood vessel development has been established\textsuperscript{72}. Furthermore, TGF-β1 stimulates VEGF and connective tissue growth factor (CTGF) expression\textsuperscript{73}. CTGF stimulates increased expression of ECM fibronectin, collagen 1, and laminin, while CTGF knockdown inhibits ECM production induced by TGF-β1 in human mesothelial cells\textsuperscript{73}.

CURRENT PREVENTION THERAPIES

**Rules of disengagement**

Single therapeutic strategies have failed to completely prevent peritoneal adhesions because of the multifactorial nature of adhesion pathogenesis\textsuperscript{74}. As these multifactorial etiologies act independently and synergistically in adhesion formation, it is imperative to simultaneously address the major molecular aberrations, including reduction of tPA and upregulation of TGF-β1 and HIF-1α, for any therapeutic strategy to be successful. The current preventive approaches of reducing surgical trauma, use of physical barriers or administration of single pharma-
Surgical precautions

The general surgical precautions aiming at minimizing surgical trauma include meticulous surgical techniques, delicate purposeful tissue handling, achieving optimal hemostasis, minimizing the risk of infection, and avoiding contaminants (e.g., fecal matter) and the use of foreign materials (e.g., talcum powder) when possible. However, these surgical techniques alone are not effective.

Physical barriers

Physical barriers work by separating surgically injured tissues during the initial postoperative time period while remesothelialization is occurring, a process that is usually expected to take three to five days. Currently, three barriers, Interceed® (Johnson and Johnson, Gynecare, Somerville, NJ), Sepafilm® (Genzyme, Cambridge, MA), and ADEPT® (Baxter, Deerfield, IL), are approved by the Food and Drug Administration (FDA) for clinical use in the United States. Although barriers have shown some success, this experience is not universally confirmed. In fact, the FDA warns surgeons that when Interceed is used laparoscopically, patients have more adhesions than patients in the control group. In the United States, ADEPT is only approved for laparoscopic gynecological surgery, and is contraindicated for patients with infection or allergies to cornstarch, as well as procedures involving laparotomy incision, bowel resection, or appendectomy. If used in these contraindicated procedures, patient may experience dehiscence, cutaneous fistula formation, anastomotic failure, ileus, and/or peritonitis. Thus, application and adoption of this product have been very limited. Furthermore, the surgeon must predict the potential sites of adhesion formation in order to determine the placement site and to optimize barrier function.

Molecular therapy

A multitude of pharmacological agents, including recombinant proteins and antibodies, have demonstrated moderate success in reducing adhesion formation in different experimental adhesion models. These agents are applied locally into the peritoneal cavity, and work by correcting aberrant molecular pathways operative during adhesion development. One of the most extensively studied pharmacological agents that has demonstrated consistent success is recombinant tPA (reviewed in Ref 92). Experimental studies have reported reduction in adhesion formation and reformation using intraperitoneal recombinant human tPA in a variety of delivery methods and preparations, without impairing the healing of bowel anastomosis and without reduction in wound strength or causing hemorrhagic complications. The action of tPA is localized to fibrin deposits; therefore, fibrinolytic activity is limited to this site, which prevents indiscriminate fibrinolysis. Similar experiences were obtained in studies using neutralizing antibodies for PAI-1, TGF-β, TNF-α and IL-1, IL-6, and for VEGF. However, these agents have short half-lives (few minutes) limiting their fibrinolytic effect for a sufficient duration of time (three to five days) until complete healing of peritoneal surfaces.

Gene therapy

Local molecular therapy is inherently limited; therefore, an alternative strategy using gene therapy has been recently employed to correct molecular aberrations induced by surgical trauma in a regulated manner during the period of remesothelialization. Postoperative peritoneal adhesion is an attractive target for gene therapy because of several inherent biological features. The disease is localized to the site of peritoneal trauma and develops over a short period of time, extending for the first few days following surgical trauma. These characteristics lend themselves perfectly to gene therapy using non-integrating vectors. The vector can be applied locally following completion of the operation, and the short duration of gene expression would cover the period of altered molecular aberrations (e.g., depressed tPA, elevated PAI-1, TGF-β, HIF-1α, etc.) following surgery. Nevertheless, gene therapy for peritoneal adhesions is still in its infancy, with very few in vivo studies reported in the literature (Table 1).

Using different vectors, the five gene therapy studies reported in the literature were able to express therapeutic nucleic acids (transgenes or small interfering RNA) in the peritoneal tissues after intra-peritoneal administration in a rat adhesion model for at least seven days post-administration. This duration of expression is enough.
Given the unresolved safety limitations of viral vectors, significant research efforts have been directed towards virology and non-viral delivery systems. Delivery of therapeutic nucleic acid molecules to target tissues is accomplished using either viral vectors or non-viral carrier systems. Replication-deficient recombinant adenovirus vectors have become the most widely used viral vectors for in vivo gene transfer. Adenovirus vectors have many positive attributes, including their ability to provide efficient in vivo gene transfer to both dividing and non-dividing cells, their high in vivo stability, and their non-integrating nature into the host genome. These merits make adenoviral vectors suitable for proof-of-principle experimental studies. However, the clinical application of virus-mediated gene delivery in vivo is hampered by virus-induced acute inflammation, which could be fatal, high immunogenicity, and low tissue specificity. The broad tropism of adenovirus allows the virus to infect many cell types and is responsible for virus dissemination to distant organs. Various modifications of adenoviral vectors are underway to enhance the targeting of adenoviral vectors towards adhesion fibroblasts, which will provide effective and safe methods for localized treatment of postoperative peritoneal adhesions.

Prospects

Gene therapy for the prevention of peritoneal adhesions has not been fully explored. Two potential developments for safe and effective gene therapy studies for adhesion prevention include combinatorial gene therapy and vector modifications.

COMBINATORIAL GENE THERAPY

The multifactorial nature of adhesion formation proposes that a combinatorial gene therapy would be more efficacious than a single gene therapy approach. For example, this could include overexpression of the fibrinolytic factor PAI-1 and/or HIF-1α. Overexpression is achieved through delivery of an exogenous gene, while downregulation is accomplished by the delivery of small interfering RNA (siRNA) molecules. Upon delivery, siRNAs complement with specific mRNAs resulting in their degradation, thus enabling the specific silencing of a single gene at the cellular level. As discussed above, single gene overexpression or silencing was moderately successful in reducing experimental adhesions. The synergistic effects from the combined fibrinolysis stimulation and fibrogenesis inhibition, however, remain to be confirmed.

SAFE AND EFFICIENT VECTORS

Viral vectors

Delivery of therapeutic nucleic acid molecules to target tissues is accomplished using either viral vectors or non-viral carrier systems. Replication-deficient recombinant adenovirus vectors have become the most widely used viral vectors for in vivo gene transfer. Adenovirus vectors have many positive attributes, including their ability to provide efficient in vivo gene transfer to both dividing and non-dividing cells, their high in vivo stability, and their non-integrating nature into the host genome. These merits make adenoviral vectors suitable for proof-of-principle experimental studies. However, the clinical application of virus-mediated gene delivery in vivo is hampered by virus-induced acute inflammation, which could be fatal, high immunogenicity, and low tissue specificity. The broad tropism of adenovirus allows the virus to infect many cell types and is responsible for virus dissemination to distant organs. Various modifications of adenoviral vectors are underway to enhance the targeting of adenoviral vectors towards adhesion fibroblasts, which will provide effective and safe methods for localized treatment of postoperative peritoneal adhesions.

Nonviral vectors

Given the unresolved safety limitations of viral vectors, significant research efforts have been directed towards nonviral gene delivery systems. These include liposomes, synthetic polymers, and cationic polymers containing siRNAs to PAI-1 and HIF-1α. Overexpression of PAI-1 is attenuated by overexpressing its down-stream Smad2/3 natural inhibitor Smad7 using plasmid vector. The moderate success in adhesion reduction in these gene therapy studies supports the concept that the multifactorial nature of molecular aberration during adhesion formation should be collectively and simultaneously addressed for any therapeutic strategy to be effective. This concept does not contradict, but reinforces, the established hypothesis of the central role of tPA in vivo gene transfer. Adenovirus vectors have many positive attributes, including their ability to provide efficient in vivo gene transfer to both dividing and non-dividing cells, their high in vivo stability, and their non-integrating nature into the host genome. These merits make adenoviral vectors suitable for proof-of-principle experimental studies. However, the clinical application of virus-mediated gene delivery in vivo is hampered by virus-induced acute inflammation, which could be fatal, high immunogenicity, and low tissue specificity. The broad tropism of adenovirus allows the virus to infect many cell types and is responsible for virus dissemination to distant organs. Various modifications of adenoviral vectors are underway to enhance the targeting of adenoviral vectors towards adhesion fibroblasts, which will provide effective and safe methods for localized treatment of postoperative peritoneal adhesions.

Figure 2 Correlation analysis was performed using two-tailed Spearman rank correlation test between tPA with respect to PAI-1 (line A, marker □), TIMP-1 (line B, marker ○), TGF-β1 (line C, marker △) or adhesion score (line D, marker ◇). Values of tPA, PAI-1, TIMP-1, and TGF-β1 concentration in adhesion tissues were logarithmically transformed to obtain a normal distribution before statistical analysis. There was significant negative correlations ($r < 0.01$) between human tPA and either of PAI-1 (Spearman rank correlation coefficient, $r = 0.89$), TIMP-1 ($r = 0.73$), TGF-β1 ($r = 0.87$), or adhesion score ($r = 0.87$), tPA: Tissue plasminogen activator; PAI-1: Plasminogen activator inhibitor 1; TIMP-1: Tissue inhibitors of MMP; TGF-β1: Transforming growth factor-β.
the development of non-viral (plasmid-based) delivery systems. Plasmids are extrachromosomal genetic elements able to replicate autonomously and to be maintained in a host cell. Plasmids, the most basic forms of non-viral gene therapy, carry two main units: a eukaryotic transcription cassette and the bacterial amplification unit (Figure 3). The first bears genetic elements intended for gene expression in mammalian (eukaryotic) cells, such as the enhancer/promoter sequences for gene expression; 5′ untranslated region (5′ UTR), the gene of interest and polyadenylation (polyA) sequence. The bacterial amplification unit commonly contains an origin for plasmid DNA replication (ori) in bacteria and, generally, an antibiotic resistance selection marker. Plasmids do not enter cells efficiently because of their large size, hydrophilic nature (due to negatively charged phosphate groups), and their susceptibility to nuclease-mediated degradation. Plasmid DNA and siRNA are stable for only 0.5 and 2 h, respectively, in human serum. Plasmids can be delivered to cells either naked (carrier-free) by direct injection, electroporation, ultrasound etc., or complexed with cationic lipids (lipoplexes), cationic polymers (polypelexes), peptides or inorganic nanoparticles. Two promising recent modifications of plasmid vectors, minicircles and CpG-depleted vectors, are briefly discussed below. Evaluating the rapid progress in the field of cationic liposomes and polymers is, however, beyond the scope of this brief review, and the reader is referred to excellent recent reviews.

**Minicircle vectors**

Limitations of conventional DNA plasmid vectors are related to their size (> 3 kb). Moreover, bacterial sequences contain immunotoxic cytidine-phosphate-guanosine (CpG) dinucleotides motifs, which are approximately four times more prevalent in bacterial than mammalian DNA. Bacterial CpG dinucleotides have been identified to be major contributors to the low and short-lived transgene expression (transgene silencing) in vertebrates after non-viral gene delivery. These bacterial sequences can also interfere with short hairpin RNA (shRNA, precursor of siRNA) expression. To overcome these limitations, highly safe and efficient vector systems for gene transfer in eukaryotic cells called minivectors (minicircles) were developed. Minicircles are supercoiled minimal expression cassettes, derived from conventional plasmid DNA by site-specific recombination in vivo in Escherichia coli. As a result, two well-defined circular molecules are generated from the parent conventional plasmid, termed minicircle (mammalian expression cassette) and miniplasmid (bacterial backbone elements). Further purification of the minicircle renders it therapeutically applicable. Thus, minicircle DNA lacks the bacterial backbone sequence consisting of an antibiotic resistance gene and an origin of replication. Minicircle DNA is low in immunogenicity due to its lower content of bacterial unmethylated CpG dinucleotides. In addition to their improved safety profile, minicircles have been shown to greatly increase the efficiency of transgene expression in various in vitro and in vivo studies, compared to the conventional plasmid with the same transgene expression cassette. It has been reported that a minivector incorporating short hairpin RNA efficiently transfected adhesion fibroblasts and was shown to be stable in human serum for > 48 h.

**CpG-depleted vectors**

Bacterial DNA is rich in unmethylated CpG dinucleotides, in contrast to mammalian DNA, which contains a low frequency of CpG dinucleotide, which are mostly methylated. Recognition of unmethylated CpGs present in the bacterial backbone could trigger an innate immune response following detection in the endosome by toll-like receptor 9 (TLR9) and initiate a signaling cascade, leading to the production of proinflammatory cytokines. As plasmids used in in vivo gene therapy studies are produced in Escherichia coli (E. coli), their CpGs are unmethylated and induce immune responses through this host defense mechanism. Recently, plasmids that are completely devoid of CpG dinucleotides have been developed. These plasmids yield high levels of transgene expression both in vitro and in vivo, and, in contrast to CMV-based plasmids, allow sustained expression in vivo. In these CpG-free plasmids, all elements required for replication and selection of the plasmid in E. coli and for gene expression in mammalian cells (e.g., promoter, polyadenylation signal, reporter gene, etc.) either naturally lack CpG dinucleotides, were modified to remove all CpGs, or are entirely synthesized.

**CONCLUSION**

Gene therapy for the prevention of postoperative peritoneal adhesions is still in its infancy. The potential applications of this strategy have not been fully explored. The recent explosive progress in advanced nonviral gene delivery systems, coupled with the newly developed less immunogenic and more efficient expression plasmids, will undoubtedly accelerate research studies in gene therapy for peritoneal adhesions.
REFERENCES

1. Parker MC, Wilson MS, van Goor H, Moran BJ, Jeekel J, Duron JJ, Menzies D, Wexner SD, Ellis H. Adhesions and colorectal surgery - call for action. Colorectal Dis 2007; 9 Suppl 2: 66-72.

2. Liakakos T, Thomakos N, Fine PM, Dervenis C, Young RL. Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management. Dig Surg 2001; 18: 260-273.

3. Cheong YC, Laird SM, Li TC, Shelton JB, Ledger WL, Cooke ID. Peritoneal healing and adhesion formation/reformation. Hum Reprod Update 2001; 7: 556-566.

4. Gutt CN, Oniu T, Schenmer P, Mehrabi A, Büchler MW. Fewer adhesions induced by laparoscopic surgery? Surg Endosc 2004; 18: 898-906.

5. Krähenbühl L, Schäfer M, Kuzinkovas V, Renzulli P, Baer HU, Büchler MW. Experimental study of adhesion formation in open and laparoscopic fundoplication. Br J Surg 1998; 85: 826-830.

6. Garrard CL, Clements RH, van Hall EV, Nanney LD, Davidson JM, Rich RA, Kotseos K, Zhao Y, Bennett B, McLean FW, Paterson-Brown S, Harbourne T, Whawell S, Vipond MN, Thompson J, Bergström M, Eriksson E, al-Jabreen M, Risberg B. Fibrinolytic response to elective surgery. Br J Surg 1987; 74: 976-980.

7. Ray NF, Larsen JW, Stillman RJ, Jacobs RJ. Economic impact of hospitalizations for lower abdominal adhesiolysis in the United States in 1988. Surg Gynecol Obstet 1993; 176: 271-276.

8. Ray NF, Denton WG, Thamer M, Henderson SC, Perry S. Abdominal adhesiolysis: inpatient care and expenditures in the United States in 1994. J Am Coll Surg 1998; 186: 1-9.

9. Ellis H, Crowe A. Medico-legal consequences of post-operative intra-abdominal adhesions. Int J Surg 2009; 7: 187-191.

10. Wiseman DM, Trout JR, Diamond MP. The rates of adhesion development and the effects of crystalloid solutions on adhesion development in pelvic surgery. Fertil Steril 1998; 70: 702-711.

11. Raftery AT. Regeneration of parietal and visceral peritoneum: an electron microscopic study. J Anat 1973; 115: 375-392.

12. diZerega GS, Campeau JD. Peritoneal repair and post-surgical adhesion formation. Hum Reprod Update 2001; 7: 547-555.

13. Alpay Z, Saed GM, Diamond MP. Postoperative adhesions: from formation to prevention. Semin Reprod Med 2008; 26: 313-321.

14. Holmdahl L, Eriksson E, Eriksson BI, Risberg B. Depression of peritoneal fibrinolysis during operation is a local response to trauma. Surgery 1998; 123: 539-544.

15. Ivarsson ML, Bergström M, Eriksson E, Risberg B, Holmdahl L. Tissue markers as predictors of postoperative adhesions. Br J Surg 1998; 85: 1549-1554.

16. Holmdahl L, Kotsos K, Bergström M, Falk P, Ivarsson ML, Chegini N. Overproduction of transforming growth factor-beta 1 (TGF-beta 1) is associated with adhesion formation and peritoneal fibrinolytic impairment. Surgery 2001; 129: 626-632.

17. Chegini N, Kotsos K, Zhao Y, Bennett B, McLean FW, Diamond MP, Holmdahl L, Burrs J. Differential expression of TGF-beta 1 and TGF-beta 3 in serosal tissues of human intra-peritoneal organs and peritoneal adhesions. Hum Reprod 2001; 16: 1291-1300.

18. Cheong YC, Shelton JB, Laird SM, Li TC, Ledger WL, Cooke ID. Peritoneal fluid concentrations of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and transforming growth factor-beta in women with pelvic adhesions. Fertil Steril 2003; 79: 1169-1175.

19. Molinas CR, Campo R, Elkelani OA, Binda MM, Carmeliet P, Koninckx PR. Role of hypoxia inducible factors 1alpha and 2alpha in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice. Fertil Steril 2003; 80 Suppl 2: 795-802.

20. Segura T, Schmolck H, Hubbell JA. RNA interference targeting hypoxia inducible factor 1alpha reduces post-operative adhesions in rats. J Surg Res 2007; 141: 162-170.

21. Cahill RA, Wang JH, Soohkai S, Redmond HP. Mast cells facilitate local VEGF release as an early event in the pathogenesis of postoperative peritoneal adhesions. Surgery 2006; 140: 108-112.

22. Thompson JN, Paterson-Brown S, Harbourne T, Whawell SA, Kalodiki E, Dudley HA. Reduced human peritoneal plasminogen activating activity: possible mechanism of adhesion formation. Br J Surg 1989; 76: 382-384.

23. Holmdahl L, Falkenberg M, Ivarsson ML, Risberg B. Plasminogen activators and inhibitors in peritoneal tissue. AP-AMS 1997; 105: 25-30.

24. Holmdahl L, Eriksson E, al-Jabreen M, Risberg B. Fibrinolysis in human peritoneum during operation. Surgery 1996; 119: 701-705.

25. Scott-Coombes D, Whawell S, Wipond MN, Thompson J, Human intraperitoneal fibrinolytic response to elective surgery. Br J Surg 1995; 82: 414-417.

26. Sulaiman H, Dawson L, Laurent GJ, Bellingan GJ, Herrick SE. Role of plasminogen activators in peritoneal adhesion formation. Biochem Soc Trans 2002; 30: 126-131.

27. Routh UK, Diamond MP. Role of plasminogen activators during healing after uterine serosal lesioning in the rat. Fertil Steril 2003; 79: 138-145.

28. Brokelman WJ, Holmdahl L, Janssen IM, Falk P, Bergström M, Klinkenbijl JH, Reijnen MM. Decreased peritoneal tissue plasminogen activator during prolonged laparoscopic sur-
Atta HM. Gene therapy for peritoneal adhesions

gery. J Surg Res 2009; 151: 89-93

40 Molinas CR, Elkeiari O, Campo R, Luttun A, Carmeliet P, Koninckx PR. Role of the plasminogen system in basal adhesion formation and carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice. Fertil Steril 2003; 80: 184-192

41 Chegini N, Kotsos K, Bennett B, Diamond MP, Holmahl L, Burme J. Matrix metalloproteinase (MMP-1) and tissue inhibitor of MMP in peritoneal fluids and sera and correlation with peritoneal adhesions. Fertil Steril 2001; 76: 1207-1211

42 Martin J, Yung S, Robson RL, Steadman R, Davies M. Production and regulation of matrix metalloproteinases and their inhibitors by human peritoneal mesothelial cells. Dial Dial Int 2000; 20: 524-533

43 Chegini N, Kotsos K, Zhao Y, Ma C, McLean F, Diamond MP, Holmahl L, Burme J. Expression of matrix metalloproteinase (MMP-1) and tissue inhibitor of MMP in serosal tissue of intraperitoneal organs and adhesions. Fertil Steril 2001; 76: 1212-1219

44 Haney AF. Identification of macrophages at the site of peritoneal injury: evidence supporting a direct role for peritoneal macrophages in healing injured peritoneum. Fertil Steril 2000; 73: 988-995

45 Gory DA, Herrick SE, Shah M, Ferguson MW. Experimental manipulation of transforming growth factor-beta isotypes significantly affects adhesion formation in a murine surgical model. Am J Pathol 2005; 167: 1005-1019

46 Whawell SA, Thompson JN. Cytokine-induced release of plasminogen activator inhibitor-1 by human mesothelial cells. Eur J Surg 1995; 161: 315-318

47 Chegini N, Rong H, Bennett B, Stone IK. Peritoneal fluid cytokine and eicosanoid levels and their relation to the incidence of peritoneal adhesion. J Soc Gynecol Investtg 1999; 6: 153-157

48 Ghelalai AM, Stucchi AF, Chegini N, Ma C, Andry CD, Kaset JM, Burns JW, Skinner KC, Becker JM. Role of transforming growth factor beta-1 in peritonitis-induced adhesions. J Gastrointest Surg 2004; 4: 316-323

49 Falk P, Ma C, Chegini N, Holmahl LD. Differential regulation of mesothelial cell fibrinolysis by transforming growth factor beta 1. Scand J Clin Lab Invest 2003; 60: 439-447

50 Tietze L, Elbrecht A, Schaauerte C, Klosterhalfen B, Amo-バイク K, Gehlen J, Winkeltau G, Mittermayer C, Hands T. Modulation of pro- and antifibrinolytic properties of human peritoneal mesothelial cells by transforming growth factor beta 1 (TGF-beta1), tumor necrosis factor alpha (TNF-alpha) and interleukin 1beta (IL-1beta). Thromb Haemost 1998; 79: 362-370

51 Williams RS, Rossi AM, Chegini N, Schultz G. Effect of transforming growth factor beta on postoperative adhesion formation and intact peritoneum. J Surg Res 1992; 52: 65-70

52 Lucas PA, Warejcke DJ, Young HE, Lee BY. Formation of abdominal adhesions is inhibited by antibodies to transforming growth factor-beta 1. J Surg Res 1996; 65: 135-138

53 Freeman ML, Saed GM, Elhammady EF, Diamond MP. Expression of transforming growth factor beta isoforms mRNA in injured peritoneum that healed with adhesions and without adhesions and in uninjured peritoneum. Fertil Steril 2003; 80 Suppl 2: 708-713

54 Saed GM, Zhang W, Chegini N, Holmahl L, Diamond MP. Alteration of type I and III collagen expression in human peritoneal mesothelial cells in response to hypoxia and transforming growth factor-beta 1. Wound Repair Regen 1999; 7: 504-510

55 Saed GM, Zhang W, Diamond MP. Molecular characterization of fibroblasts isolated from human peritoneum and adhesions. Fertil Steril 2001; 75: 765-768

56 Ma C, Tarnuzzer RW, Chegini N. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in mesothelial cells and their regulation by transforming growth factor-beta1. Wound Repair Regen 1999; 7: 477-485

57 Chegini N. The role of growth factors in peritoneal healing: transforming growth factor beta (TGF-beta). Eur J Surg Suppl 1997; 17-23

58 Bourdel N, Matsuzaki S, Bazin JE, Pouly JL, Mage G, Canis M. Peritoneal tissue-oxygen tension during a carbon dioxide pneumoperitoneum in a mouse laparoscopic model with controlled respiratory support. Hum Reprod 2007; 22: 1149-1155

59 Molinas CR, Myryba E, Pauwels A, Novak P, Koninckx PR. Peritoneal mesothelial hypoxia during pneumoperitoneum is a cofactor in adhesion formation in a laparoscopic mouse model. Fertil Steril 2001; 76: 560-567

60 Saed GM, Galijasevic S, Diamond MP, Abu-Soud HM. Measurement of oxygen and nitric oxide levels in vitro and in vivo: relationship to postoperative adhesions. Fertil Steril 2005; 84: 235-238

61 Matsuzaki S, Canis M, Bazin JE, Darcha C, Pouly JL, Mage G. Effects of supplemental perioperative oxygen on postoperative abdominal wound adhesions in a mouse laparotomy model with controlled respiratory support. Hum Reprod 2007; 22: 2702-2706

62 Saed GM, Diamond MP. Modulation of the expression of tissue plasminogen activator and its inhibitor by hypoxia in human peritoneal and adhesion fibroblasts. Fertil Steril 2003; 79: 164-168

63 Kietzmann T, Samoylenko A, Roth U, Jungermann K. Hypoxia-inducible factor 1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood 2003; 101: 907-914

64 Saed GM, Zhang W, Chegini N, Holmahl L, Diamond MP. Transforming growth factor beta isoforms production by human peritoneal mesothelial cells after exposure to hypoxia. Am J Reprod Immunol 2000; 43: 285-291

65 Saed GM, Diamond MP. Hypoxia-induced irreversible up-regulation of type I collagen and transforming growth factor beta 1 in human peritoneal fibroblasts. Fertil Steril 2002; 78: 144-147

66 Fletcher NM, Jiang ZL, Diamond MP, Abu-Soud HM, Saed GM. Hypoxia-generated superoxide induces the development of the adhesion phenotype. Free Radic Biol Med 2008; 45: 530-536

67 Saed GM, Diamond MP. Apoptosis and proliferation of human peritoneal fibroblasts in response to hypoxia. Fertil Steril 2002; 78: 137-143

68 Diamond MP, El-Hammady E, Mukarath A, Bieber EJ, Saed G. Modulation of the expression of vascular endothelial growth factor in human fibroblasts. Fertil Steril 2005; 83: 405-409

69 Wiczyk HP, Grow DR, Adams LA, O'Shea DL, Reece MT. Pelvic adhesions contain sex steroid receptors and produce angiogenesis growth factors. Fertil Steril 1998; 69: 511-516

70 Molinas CR, Campo R, Dewerchin M, Eriksson U, Carme liet P, Koninckx PR. Role of vascular endothelial growth factor and placental growth factor in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice. Fertil Steril 2003; 80 Suppl 2: 803-811

71 Epstein JC, Wilson MS, Wilkosz S, Ireland G, O'Dwyer ST, Herrick SE. Human peritoneal adhesions show evidence of tissue remodeling and markers of angiogenesis. Dis Colon Rectum 2006; 49: 1858-1892

72 Szeto CC, Lai KB, Chow KM, Szeto CY, Wong TY, Li PK. Differential effects of transforming growth factor-beta on the synthesis of connective tissue growth factor and vascular endothelial growth factor by peritoneal mesothelial cell.
Nephron Exp Nephrol. 2005; 99: e95-e104

Xiao L, Sun L, Liu FY, Peng YM, Duan SB. Connective tissue growth factor knockdown attenuated matrix protein production and vascular endothelial growth factor expression induced by transforming growth factor-beta1 cultured human peritoneal mesothelial cells. *Ther Apher Dial* 2010; 14: 27-34

Diamond MP, Wexner SD, diZerega GS, Korril M, Zmora O, Van Goor H, Kamar M. Adhesion prevention and reduction: current status and future recommendations of a multinational interdisciplinary consensus conference. *Surg Innov* 2010; 17: 183-188

Robertson D, Lefebvre G, Leyland N, Wolfman W, Allaire C, Awadalla A, Best C, Contestabile E, Dunn S, Heywood M, Leroux N, Potestio F, Rittenberg D, Senikas V, Soucy R, Singh S. Adhesion prevention in gynaecological surgery. *J Obstet Gynaecol Can* 2010; 32: 598-608

Ward BC, Panitch A. Abdominal adhesions: current and novel therapies. *J Surg Res* 2011; 165: 91-111

Wallwiener D, Meyer A, Bastert G. Adhesion formation of the parietal and visceral peritoneum: an explanation for the controversy on the use of autologous and alloplastic barriers? *Fertil Steril* 1998; 69: 132-137

Cohen Z, Senagore AJ, Dayton MT, Koruda MJ, Beck DE, Wolff BG, Fleshner PR, Thirlby RC, Ludwig KA, Larach SW, Weiss EG, Bauer J, Holmdahl L. Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/carboxymethylcellulose-based bioreabsorbable membrane: a prospective, randomized, evaluator-blinded multicenter study. *Dis Colon Rectum* 2005; 48: 1130-1139

Buckenmaier CC, Summers MA, Hetz SP. Effect of the antiadhesive treatments, carboxymethylcellulose combined with recombinant tissue plasminogen activator and Seprafilm, on bowel anastomosis in the rat. *Am Surg* 2000; 66: 1041-1045

Doody KJ, Dunn RC, Buttram VC. Recombinant tissue plasminogen activator reduces adhesion formation in a rabbit uterine horn model. *Fertil Steril* 1989; 51: 509-512

Dörr PJ, Vemer HM, Brommer EJ, Willemson VN, Veldhuijzen RW, Rolland R. Prevention of postoperative adhesions by tissue-type plasminogen activator (t-PA) in the rabbit. *Eur J Obstet Gynecol Reprod Biol* 1990; 37: 287-291

Dunn RC, Buttram VC. Tissue-type plasminogen activator as an adjuvant for post surgical adhesions. *Prog Clin Biol Res* 1990; 358: 113-118

Dunn RC, Steinleiner AJ, Lambert H. Synergistic effect of intraperitoneally administered calcium channel blockade and recombinant tissue plasminogen activator to prevent adhesion formation in an animal model. *Am J Obstet Gynecol* 1991; 164: 1327-1330

Evans DM, McAree K, Guyton DP, Hawkins N, Stakleff K. Dose dependency and wound healing aspects of the use of tissue plasminogen activator in the prevention of intraabdominal adhesions. *Am J Surg* 1993; 165: 229-232

Gehlbach DL, O’Hair KC, Parks AL, Rosa C. Combined effects of tissue plasminogen activator and carboxymethylcellulose on adhesion reformation in rabbits. *Int J Fertil Menopausal Stud* 1994; 39: 172-176

Lai HS, Chen Y, Chang KJ, Chen WJ. Tissue plasminogen activator reduces intraperitoneal adhesion after intestinal resection in rats. *J Formos Med Assoc* 1998; 97: 323-327

Menzies D, Ellis H. Intra-abdominal adhesions and their prevention by topical tissue plasminogen activator. *J Soc Med* 1989; 82: 534-535

Montz FJ, Fowler JM, Wolff AJ, Lacey SM, Mohler M. The ability of recombinant tissue plasminogen activator to inhibit post-radical pelvic surgery adhesions in the dog model. *Am J Obstet Gynecol* 1991; 165: 1593-1592

Orita H, Fukasawa M, Girgis W, diZerega GS. Inhibition of postsurgical adhesions in a standardized rabbit model: intraperitoneal treatment with tissue plasminogen activator. *Int J Fertil* 1991; 36: 172-177

Vipond MN, Whawell SA, Scott-Coombes DM, Thompson JN, Dudley HA. Experimental adhesion prophylaxis with recombinant tissue plasminogen activator. *Ann R Coll Surg Engl* 1994; 76: 412-415

Yeo Y, Bellas E, Highley CB, Langer R, Kohane DS. Peritoneal adhesion prevention with an in situ cross-linkable hyaluronan gel containing tissue-type plasminogen activator in a rabbit repeated-injury model. *Biomaterials* 2007; 28: 3704-3713

Hellebrekers BW, Trimbos-Kemper TC, Trimbos JB, Emeis JJ, Kooistra T. Use of fibrinolytic agents in the prevention of postoperative adhesion formation. *Fertil Steril* 2000; 74: 203-212

Menzies D, Ellis H. The role of plasminogen activator in adhesion prevention. *Surg Gynecol Obstet* 1991; 172: 362-366

Falk K, Björquist P, Strömqvist M, Holmdahl L. Reduction of experimental adhesion formation by inhibition of plasminogen activator inhibitor type 1. *Br J Surg* 2001; 88: 286-289

Zhang Z, Garron TM, Li XJ, Liu Y, Zhang X, Li YY, Xu WS. Recombinant human decorin inhibits TGF-beta1-induced contraction of collagen lattice by hypotrophic scar fibroblasts. *Burns* 2009; 35: 527-537

Kaidi AA, Nazzal M, Gurchumelidze T, Ali MA, Dawe EJ, Silva YJ. Preoperative administration of antibodies against tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) and their impact on peritoneal adhesion formation. *Am Surg* 1995; 61: 569-572

Saba AA, Kaidi AA, Goudzhiwili V, Donhi GW, Dawe EJ, Lücke JH, Silva YJ. Effects of interleukin-6 and its neutralizing antibodies on peritoneal adhesion formation and wound healing. *Am Surg* 1996; 62: 569-572

Ignjatovic D, Aasland K, Peetersen M, Sund S, Chen Y, Spasojevic M, Nesgaard JM. Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions. *Am J Surg* 2010; 200: 270-275

Saltzman AK, Olson TA, Mohranr D, Carson LF, Ramakrishnan S. Prevention of postoperative adhesions by an antibody to vascular permeability factor/vascular endothelial growth factor in a murine model. *Am J Obstet Gynecol* 1996; 174: 1502-1506

Hellebrekers BW, Trimbos-Kemper TC, Boesten L, Jansen FW, Kolkmann W, Trimbos JB, Press RR, van Poelegist MI, Emeis SJ, Kooistra T. Preoperative predictors of postsurgical adhesion formation and the Prevention of Adhesions with Plasminogen Activator (PAPA-study): results of a clinical pilot study. *Fertil Steril* 2009; 91: 1204-1214

Alta HM, Al-Hendy A, El-Rehany MA, Dewerchin M, Abdel Raheim SR, Abdel Ghany H, Fouad R. Adenovirus-mediated overexpression of human tissue plasminogen activator prevents peritoneal adhesion formation/refomation in rats. *Surgery* 2009; 146: 12-17

Guo H, Leung JC, Cheung JS, Chan LY, Wu EX, Lai KN. Non-viral Smad7 gene delivery and attenuation of postoperative peritoneal adhesion in an experimental model. *Br J Surg* 2009; 96: 1323-1335

Guo Q, Li QF, Liu HJ, Li R, Wu CT, Wang LS. Sphinogosine kinase 1 gene transfer reduces postoperative peritoneal adhesion in an experimental model. *Br J Surg* 2008; 95: 252-258

Liu HJ, Wu CT, Duan HF, Wu B, Lu ZZ, Wang L. Adenoviral-mediated gene expression of hepatocyte growth factor prevents postoperative peritoneal adhesion in a rat model. *Surgery* 2006; 140: 441-447

Rodriguez EG. Nonviral DNA vectors for immunization and therapy: design and methods for their obtention. *J Mol Med (Berl)* 2004; 82: 500-509

Atta HM. Gene therapy for peritoneal adhesions
Zhao N, Fogg JM, Zechiedrich L, Zu Y. Transfection of shRNA-encoding Minivector DNA of a few hundred base pairs to regulate gene expression in lymphoma cells. *Gene Ther* 2011; 18: 220-224

Al-Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent progress. *AAPS J* 2009; 11: 671-681

Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. *Biomaterials* 2000; 29: 3477-3496

Gill DR, Pringle IA, Hyde SC. Progress and prospects: the design and production of plasmid vectors. *Gene Ther* 2009; 16: 165-171

Mayrhofer P, Schleef M, Jechlinger W. Use of minicircle plasmids for gene therapy. *Methods Mol Biol* 2009; 542: 87-104

Hattori K, Nishikawa M, Watcharanurak K, Ikoma A, Kabashima K, Toyota H, Takahashi Y, Takahashi R, Watanabe Y, Takakura Y. Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. *J Immunol* 2010; 184: 2729-2735

Lesina E, Dames P, Rudolph C. The effect of CpG motifs on gene expression and clearance kinetics of aerosol administered polyethylenimine (PEI)-plasmid DNA complexes in the lung. *J Control Release* 2010; 143: 243-250

S- Editor Sun H L- Editor Stewart GJ E- Editor Zhang DN